The risk of patient harm more than doubled in 2006, when teaching hospitals nationwide embraced the pursuit of minimally invasive robotic surgery for prostate cancer, a new study conducted by researchers at University of California, San Diego School of Medicine and published in JAMA Surgery reveals.
"This study looked at the stages of innovation and how the rapid adoption of a new surgical technology—in this case, a surgical robotic system—can lead to adverse events for patients," said Kellogg Parsons, MD, MHS, surgical oncologist, UC San Diego Health System and first author of the paper. "There is a real need for standardized training programs, rules governing surgeon competence and credentialing, and guidelines for hospital privileging when novel technologies reach the operating rooms of teaching and community hospitals."
In 2003, there were an estimated 617 minimally invasive robotic prostatectomies (MIRPs) performed in the United States. By 2009, this number increased to 37,753 procedures. In 2005, patients were twice as likely to experience an adverse event if they were undergoing MIRPs compared to a traditional open surgical procedure. The following year - was considered the tipping point for the adoption of MIRP when it equaled or exceeded 10 percent of all cases.
Kane added that robotic prostatectomy by experienced surgeons has proven to be beneficial to the patient with less blood loss, reduced infections and shorter hospital stays.
"A responsibility of deploying a surgical technology should include the responsibility to monitor it as it diffuses throughout the real world to ensure safety," said David C. Chang, PhD, MPH, MBA, director of Outcomes Research at UC San Diego School of Medicine and the paper's senior author. "Surveillance of surgical safety should be ongoing, much like the Centers for Disease Control monitor changes in trends of infectious diseases across the country."
The UC San Diego team used Patient Safety Indicators, developed by the Agency for Healthcare Research and Quality (AHRQ), to develop a nationwide data sample to analyze surgical provider performance and potential in-hospital adverse events from 2003-2009. Data for the prevalence of robotic prostatectomy was pulled from AHRQ and compared to published data from Intuitive Surgical Inc., the manufacturer of the da Vinci robotic system.
"One potential intervention would be the development of standardized training and credentialing programs, much like the aviation industry requires of flight crews inexperienced with new types of aircraft," said Parsons, who is also an associate professor of surgery at UC San Diego School of Medicine. "An independent, continuously updated tracking system for the adoption of new surgical technology is also essential. Prior estimates of robotic prostatectomy uptake, provided exclusively by the robot manufacturer, substantially overestimated the speed with which it was adopted by the surgical community."